Physician profile
Michael Han
NPI 1346489689
$18,230.38
in general payments reported to CMS, 2019-2025
68 companies · $4,243 in 2025
The $4,243 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,517 · 2020: $369 · 2021: $1,862 · 2022: $2,882 · 2023: $3,191 · 2024: $4,167 · 2025: $4,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,580.56 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,177.10 | 2020-2025 | |
| Biogen, INC. | $1,520.95 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Pfizer INC. | $1,075.97 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $788.93 | 2021-2025 | Hyqvia, Gammagard Liquid |
| Alexion Pharmaceuticals, INC. | $770.49 | 2019-2025 | Ultomiris, Soliris |
| Amgen INC. | $763.19 | 2019-2025 | Uplizna |
| Grifols USA, LLC | $662.14 | 2019-2025 | Gamunex-C |
| Sk Life Science, INC. | $648.36 | 2022-2025 | |
| Emd Serono, INC. | $638.42 | 2019-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $617.42 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $587.40 | 2019-2025 | Vyepti, Rexulti |
| Eisai INC. | $572.82 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $506.29 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Argenx US, INC. | $456.79 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Lilly USA, LLC | $455.95 | 2019-2025 | Amyvid, Kisunla, Reyvow |
Show all 67 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.